company
Cipla USA, Inc.
Jurisdiction: US
FDA Warning Letter timeline
V1 scope: FDA Warning Letters only. Additional public-record sources (SEC, CPSC, federal contracts) are on the V2 roadmap and are not surfaced here today.
- fda_recall · drug_recall2026-04-22Cipla USA, Inc. — Class II recall: Cinacalcet Hydrochloride Tablets, 90 mg, 30 Tablets per bottle, Rx Only, Manufac…
- fda_recall · drug_recall2026-04-22Cipla USA, Inc. — Class II recall: Cinacalcet Hydrochloride Tablets, 30 mg, 30 Tablets per bottle, Rx Only, Manufac…
- fda_recall · drug_recall2026-04-22Cipla USA, Inc. — Class II recall: Cinacalcet Hydrochloride Tablets, 60 mg, 30 Tablets per bottle, Rx Only, Manufac…
- fda_recall · drug_recall2026-04-15Cipla USA, Inc. — Class II recall: Lanreotide Injection, 120 mg*/0.5 mL, Box contains 1 Pre-filled syringe and 1 sa…
- fda_recall · drug_recall2026-04-15Cipla USA, Inc. — Class II recall: Lanreotide Injection, 120 mg/0.5 mL, Box contains 1 Pre-filled syringe, Single d…
Frequently asked questions
- How many FDA warning letters has Cipla USA, Inc. received?
- Argus HQ has not recorded an FDA warning letter for Cipla USA, Inc. in our current dataset.
- What FDA recalls has Cipla USA, Inc. issued?
- Argus HQ has recorded 5 FDA recalls tied to Cipla USA, Inc..
- Is Cipla USA, Inc. FDA compliant?
- Argus HQ is not a compliance rating service. As of this page's last update, our dataset shows 0 warning letters, 5 recalls, and 0 approval records for Cipla USA, Inc.. Review the linked FDA source records directly before drawing a compliance conclusion.
Informational only. FDA Warning Letters are public records (17 USC §105). Summaries are AI-assisted and may contain errors; always verify against the original FDA letter before acting. Not legal, financial, or regulatory advice.